Adjuvant chemotherapy may improve survival of patients with colon cancer stage 2 -
Researchers and doctors have addressed the role of "adjuvant" or post- surgery, chemotherapy for patients with early colon cancer -stage, even for cancers considered high risk. Now researchers from the University of Illinois at Chicago have found an association between the use of adjuvant chemotherapy in cancer stage 2 colon and improved survival - regardless of age or risk, or even chemotherapy, a patient-specific administered
results are published in the journal cancer .
The American Cancer Society estimates that over 95,000 people in the US will be diagnosed with colon cancer this year, making it the third most frequent cancer diagnosed in men and women in the States STATES It is the second leading cause of cancer deaths.
adjuvant chemotherapy has long been proven to help patients struggling against advanced colon cancer. However, its benefit for patients with stage 2 colon cancer is unknown, and current clinical guidelines only recommend that physicians discuss this upstairs treatment option 2 patients whose cancer is considered high risk and likely to come back after surgery.
"the results of this study are very interesting, and some aspects not entirely expected," says lead author Dr. Ajay Maker, associate professor of surgery at UIC College of Medicine and director of oncology surgical lawyer for Creticos cancer Center. "for many years, studies have included, but do not focus on, 2 patients with stage colon cancer. This study, which focuses on the largest group of stage 2 patients with colon cancer to date, designed to better understand the role of adjuvant chemotherapy in patients who are fighting this type and stage of cancer specific. "
Maker and colleagues examined health information about 153.110 patients in stage 2 colon cancer in the national database on cancer. They found that patients who received adjuvant chemotherapy survived longer - in some cases, years -. Let those who do not have
"Certainly, we expected to see differences in the data," said Maker. "But to find a clinically relevant association with overall survival in all subgroups of patients, including low-risk patients is remarkable and very relevant for future research on the potential use of adjuvant chemotherapy as treatment for stage 2 colon cancer, "he said.
Maker note that any retrospective study of treatment and the effect has limits.
"We must be careful when looking for associations in retrospect," said Maker. "However, our research confirms the need for prospective studies to identify stage patients subgroups 2 colon cancer who could benefit most from the use of adjuvant chemotherapy. "
results are published in the journal cancer .
The American Cancer Society estimates that over 95,000 people in the US will be diagnosed with colon cancer this year, making it the third most frequent cancer diagnosed in men and women in the States STATES It is the second leading cause of cancer deaths.
adjuvant chemotherapy has long been proven to help patients struggling against advanced colon cancer. However, its benefit for patients with stage 2 colon cancer is unknown, and current clinical guidelines only recommend that physicians discuss this upstairs treatment option 2 patients whose cancer is considered high risk and likely to come back after surgery.
"the results of this study are very interesting, and some aspects not entirely expected," says lead author Dr. Ajay Maker, associate professor of surgery at UIC College of Medicine and director of oncology surgical lawyer for Creticos cancer Center. "for many years, studies have included, but do not focus on, 2 patients with stage colon cancer. This study, which focuses on the largest group of stage 2 patients with colon cancer to date, designed to better understand the role of adjuvant chemotherapy in patients who are fighting this type and stage of cancer specific. "
Maker and colleagues examined health information about 153.110 patients in stage 2 colon cancer in the national database on cancer. They found that patients who received adjuvant chemotherapy survived longer - in some cases, years -. Let those who do not have
"Certainly, we expected to see differences in the data," said Maker. "But to find a clinically relevant association with overall survival in all subgroups of patients, including low-risk patients is remarkable and very relevant for future research on the potential use of adjuvant chemotherapy as treatment for stage 2 colon cancer, "he said.
Maker note that any retrospective study of treatment and the effect has limits.
"We must be careful when looking for associations in retrospect," said Maker. "However, our research confirms the need for prospective studies to identify stage patients subgroups 2 colon cancer who could benefit most from the use of adjuvant chemotherapy. "
EmoticonEmoticon